SYMLIN™ (pramlintide acetate)Overview
Target population: People with diabetes using insulin
Synthetic analog of human amylin
- ß-cell hormone co-secreted with insulin
4,400+ subjects exposed to SYMLIN inover 50 clinical studies
Substantial safety database
- Most common side effect reported was mild to moderate, transient nausea